Navigation Links
Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Date:8/8/2008

1,031,007 1,251,649 1,754,114

NET LOSS $(11,002,390) $(4,801,707) $(20,956,387) $(8,159,011)

Basic and diluted

net loss per share $(0.14) $(0.07) $(0.27) $(0.11)

Shares used in

computing net

loss per share,

basic and

diluted 79,454,496 73,217,967 78,923,520 71,610,380

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF JUNE 30, 2008 AND DECEMBER 31, 2007

June 30, December 31,

2008 2007

(unaudited)

ASSETS:

Cash and cash equivalents $82,410,139 $97,679,085

Accounts receivable 1,160,990 779,825

Inventory 649,254 703,468

Prepaid expenses and other assets 1,895,820 2,014,680

Total current assets 86,116,203 101,177,058

Property and equipment, net 2,439,765 2,283,316

Total Assets $88,555,968 $103,460,374

LIABILITIES AND STOCKHOLDERS' EQUITY:

Accounts payable $2,814,512 $3,055,637

Accrued expenses 3,338,896 2,502,259

Deferred revenue 3,255,461 3,306,225

Total current liabilities 9,408,869 8,864,121

Deferred revenue, net of current portion 38,376,170 35,963,266

Deferred rent, net of current portion 1,116,892 865,063

Stockholders' Equity:

Common stock 80,099 77,904

Additional paid-in capital 125
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
2. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
3. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
8. Halozyme Therapeutics Amends Stockholder Rights Plan
9. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
10. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
11. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a finalist for the ... Tech Awards. , Now in its 22nd year, this premier awards event celebrates the ... the nation and around the world. The OC Tech Alliance will announce all winners ...
(Date:8/28/2015)... According to a new market ... Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem ... User - Global Forecast to 2020", published by MarketsandMarkets, ... 3,731.03 Million by 2020 from USD 2,150.48 Million in ... and 2020. Browse 74 Tables and ...
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of ... the quarter ended June 30, 2015, corporate highlights, ... management report are available at www.sedar.com ,  ... "RepliCel expects to launch its ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... opportunity for venture capital funds, investment firms and animal health companies to hear ... have raised $160 million. Several have also received licensing agreements or distribution contracts. ...
Breaking Biology Technology:Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3
... by Strong Revenue Growth, Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET), ... Q1 2008 (millions) Q1 2007 Comparison ... 164.5% increase Naglazyme Net Product Revenue ... Aldurazyme (net sales by Genzyme) $36.8 ...
... ... - Product revenues increased 30% to a record $59.7 million ... 28,600 new pulse oximeters ... April 29, 2008 Masimo,Corporation (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and,Measure-Through-Motion-and-Low-Perfusion ...
... transmit medical images via cellular phones that has ... researcher has the potential to provide sophisticated radiological diagnoses ... lacking access to such technology. This would include millions ... areas of developed countries who live considerable distances from ...
Cached Biology Technology:BioMarin Announces First Quarter 2008 Financial Results 2BioMarin Announces First Quarter 2008 Financial Results 3BioMarin Announces First Quarter 2008 Financial Results 4BioMarin Announces First Quarter 2008 Financial Results 5BioMarin Announces First Quarter 2008 Financial Results 6BioMarin Announces First Quarter 2008 Financial Results 7BioMarin Announces First Quarter 2008 Financial Results 8BioMarin Announces First Quarter 2008 Financial Results 9BioMarin Announces First Quarter 2008 Financial Results 10BioMarin Announces First Quarter 2008 Financial Results 11Masimo Reports First Quarter 2008 Financial Results 2Masimo Reports First Quarter 2008 Financial Results 3Masimo Reports First Quarter 2008 Financial Results 4Masimo Reports First Quarter 2008 Financial Results 5Masimo Reports First Quarter 2008 Financial Results 6Masimo Reports First Quarter 2008 Financial Results 7Masimo Reports First Quarter 2008 Financial Results 8Masimo Reports First Quarter 2008 Financial Results 9Masimo Reports First Quarter 2008 Financial Results 10Researchers develop method for transmitting medical images via cell phones 2Researchers develop method for transmitting medical images via cell phones 3Researchers develop method for transmitting medical images via cell phones 4
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... from the University of Santiago de Compostela (USC) have ... The results show that the principal goal of young ... The most antisocial among them place greater importance on ... most importance on are to do with leaving home, ...
... Research currently being undertaken at the University of ... Abdominal Aortic Aneurysms (AAA) in men. In her ... into the causes of the male predominance of AAA, ... disease. Preliminary results from the study will be showcased ...
... KNOXVILLE -- By examining 800,000-year-old polar ice, scientists increasingly are ... melt and that carbon dioxide has become more abundant in ... Jrme Chappellaz has been examining ice cores collected from deep ... studies on the interconnecting air spaces of old snow -- ...
Cached Biology News:Teenagers want to finish their studies and leave home 2Increased likelihood of male death from disease 2Scientist links increase in greenhouse gases to changes in ocean currents 2
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
Biology Products: